Number of Transplant Pairs with living donors |
10/10 |
24/24 |
19/19 |
Allogenomics mismatch score AMS(SD)[range] |
1335(304)[994–2033] |
1094(259)[700–1630] |
560(147)[349–811] |
Clinical factors |
|
|
|
Age |
|
|
|
Donor (SD) |
41 (13) |
46 (10) |
44(16) |
Recipient (SD) |
48 (10) |
51 (13) |
38(15) |
Living Donor type |
|
|
|
Living related N (AMS) [SD]) |
4 (1116 [143]) |
13 (939 [218]) |
15(503[108])* |
Living unrelated N (AMS) [SD]) |
6 (1481 [300]) |
11(1277 [170]) |
4(769[41])* |
Donor sex |
|
|
|
Male (%) |
2 (20%) |
8 (33%) |
6(32%) |
Female (%) |
8 (80%) |
16 (67%) |
13(68%) |
Donor Race |
|
|
|
Black (%) |
4(40%) |
5 (21%) |
2(10%) |
Non-Black (%) |
6(60%) |
19 (79%) |
17(90%) |
Recipient sex |
|
|
|
Male (%) |
9 (90%) |
13 (54%) |
13 (53%) |
Female (%) |
1 (10%) |
11 (46%) |
13 (47%) |
Recipient Race |
|
|
|
Black (%) |
4 (40%) |
7 (29%) |
2 (10%) |
Non-Black (%) |
6 (60%) |
17 (71%) |
17 (90%) |
Number of HLA mismatches ABDR (SD) |
3.9 (1.91) |
3.5 (1.89) |
2.5 (1.68)* |
Functional Factors |
|
|
|
Number of Patients at 12 months |
10 |
24 |
17 |
Serum creatinine level at 12 months mg/dL (SD) |
1.51 (0.35) |
1.45 (0.41) |
1.29 (0.41) |
eGFR at 12 months ml/min/1.73m2 (SD) |
54.3(10) |
54.3 (16.3) |
61.8 (18.9)* |
Number of Patients at 24 months |
9 |
23 |
19 |
Serum creatinine level at 24 months mg/dL (SD) |
1.36 (0.19) |
1.45 (0.49) |
1.26 (0.3) |
eGFR at 24 months ml/min/1.73m2 (SD |
59 (7.7) |
54.85 (15.7) |
59.3 (14.5)* |
Number of Patients at 36 months |
8 |
22 |
19 |
Serum creatinine level at 36 months mg/dL(SD) |
1.62 (0.50) |
1.38 (0.40) |
1.35 (0.45) |
eGFR at 36 months ml/min/1.73m2 (SD) |
53.4 (15) |
55.3 (15.9) |
56.3 (16.4) |
Number of Patients at 48 months |
0 |
16 |
16 |
Serum creatinine level at 48 months mg/dL(SD) |
- |
1.34 (0.43) |
1.40 (0.56) |
eGFR at 48 months ml/min/1.73m2 months (SD) |
- |
57.4 (16.4) |
55.7 (18.2) |
Patients with an Acute Cellular rejection episode in the first year of transplantation, N (%) |
3 (30%) |
5 (20%) |
2 (10%) |
Immunosupression |
|
|
|
Calcineurin Inhibitors, n (%) |
9 (90%) |
24 (100%) |
19 (100%) |
Corticosteroids, n (%) |
0 (0%) |
5 (21%) |
17 (90%)* |